Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival

被引：23

作者：

Brieger, Katharine K. ^{[1
]}

Peterson, Siri ^{[1
]}

Lee, Alice W. ^{[2
]}

Mukherjee, Bhramar ^{[1
,3
]}

Bakulski, Kelly M. ^{[1
]}

Alimujiang, Aliya ^{[1
]}

Anton-Culver, Hoda ^{[4
]}

Anglesio, Michael S. ^{[5
]}

Bandera, Elisa, V ^{[6
]}

Berchuck, Andrew ^{[7
]}

Bowtell, David D. L. ^{[8
,9
]}

Chenevix-Trench, Georgia ^{[10
]}

Cho, Kathleen R. ^{[11
]}

Cramer, Daniel W. ^{[12
,13
,14
]}

DeFazio, Anna ^{[15
,16
]}

Doherty, Jennifer A. ^{[17
]}

Fortner, Renee T. ^{[18
]}

Garsed, Dale W. ^{[8
,9
]}

Gayther, Simon A. ^{[19
]}

Gentry-Maharaj, Aleksandra ^{[20
]}

Goode, Ellen L. ^{[21
]}

Goodman, Marc T. ^{[22
,23
]}

Harris, Holly R. ^{[24
,25
]}

Hogdall, Estrid ^{[26
,27
]}

Huntsman, David G. ^{[5
,28
]}

Shen, Hui ^{[29
]}

Jensen, Allan ^{[26
]}

Johnatty, Sharon E. ^{[10
]}

Jordan, Susan J. ^{[30
,31
]}

Kjaer, Susanne K. ^{[26
,32
]}

Kupryjanczyk, Jolanta ^{[33
]}

Lambrechts, Diether ^{[34
,35
]}

McLean, Karen ^{[36
]}

Menon, Usha ^{[20
]}

Modugno, Francesmary ^{[37
,38
,39
,40
]}

Moysich, Kirsten ^{[41
]}

Ness, Roberta ^{[42
]}

Ramus, Susan J. ^{[43
,44
]}

Richardson, Jean ^{[45
]}

Risch, Harvey ^{[46
]}

Rossing, Mary Anne ^{[24
,25
]}

Trabert, Britton ^{[47
]}

Wentzensen, Nicolas ^{[47
]}

Ziogas, Argyrios ^{[4
]}

Terry, Kathryn L. ^{[12
,13
,14
]}

Wu, Anna H. ^{[48
]}

Hanley, Gillian E. ^{[5
]}

Pharoah, Paul ^{[49
,50
]}

Webb, Penelope M. ^{[30
,31
,51
]}

Pike, Malcolm C. ^{[48
,52
]}

机构：

[1] Univ Michigan, Dept Epidemiol, Sch Publ Hlth, Ann Arbor, MI 48109 USA

[2] Calif State Univ Fullerton, Dept Publ Hlth, Fullerton, CA 92634 USA

[3] Univ Michigan, Dept Biostat, Sch Publ Hlth, Ann Arbor, MI 48109 USA

[4] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA

[5] Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC, Canada

[6] Rutgers Canc Inst New Jersey, Canc Prevent & Control Program, New Brunswick, NJ USA

[7] Duke Univ, Sch Med, Div Gynecol Oncol, Durham, NC USA

[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[9] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

[10] QIMR Berghofer Med Res Inst, Dept Genet & Computat Biol, Brisbane, Qld, Australia

[11] Univ Michigan, Dept Pathol, Med Sch, Ann Arbor, MI 48109 USA

[12] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA

[13] Brigham & Womens Hosp, Obstet & Gynecol Epidemiol Ctr, 75 Francis St, Boston, MA 02115 USA

[14] Harvard Med Sch, Boston, MA 02115 USA

[15] Univ Sydney, Ctr Canc Res, Westmead Inst Med Res, Sydney, NSW, Australia

[16] Westmead Hosp, Dept Gynaecol Oncol, Westmead, NSW, Australia

[17] Univ Utah, Huntsman Canc Inst, Dept Populat Hlth Sci, Salt Lake City, UT USA

[18] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany

[19] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[20] UCL, Inst Clin Trials & Methodol, MRC Clin Trials Unit UCL, London, England

[21] Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, Rochester, MN USA

[22] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Canc Prevent & Genet Program, Los Angeles, CA 90048 USA

[23] Cedars Sinai Med Ctr, Community & Populat Hlth Res Inst, Dept Biomed Sci, Los Angeles, CA 90048 USA

[24] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, 1124 Columbia St, Seattle, WA 98104 USA

[25] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA

[26] Danish Canc Soc, Dept Virus Lifestyle & Genes, Res Ctr, Copenhagen, Denmark

[27] Univ Copenhagen, Herlev Hosp, Dept Pathol, Mol Unit, Copenhagen, Denmark

[28] BC Canc Res Ctr, Dept Mol Oncol, Vancouver, BC, Canada

[29] Van Andel Res Inst VARI, Grand Rapids, MI USA

[30] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia

[31] QIMR Berghofer Med Res Inst, Dept Populat Hlth, Brisbane, Qld, Australia

[32] Univ Copenhagen, Rigshosp, Dept Gynaecol, Copenhagen, Denmark

[33] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Pathol & Lab Diagnost, Warsaw, Poland

[34] VIB, Vesalius Res Ctr, Leuven, Belgium

[35] Univ Leuven, Dept Oncol, Lab Translat Genet, Leuven, Belgium

[36] Univ Michigan, Dept Obstet & Gynecol, Div Gynecol Oncol, Med Sch, Ann Arbor, MI 48109 USA

[37] Magee Womens Res Inst, Womens Canc Res Ctr, Pittsburgh, PA USA

[38] Hillman Canc Ctr, Pittsburgh, PA USA

[39] Univ Pittsburgh, Sch Med, Div Gynecol Oncol, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA

[40] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA

[41] Roswell Park Comprehens Canc Ctr, Div Canc Prevent & Control, Buffalo, NY USA

[42] Univ Texas Hlth Sci Ctr Houston UTHlth, Sch Publ Hlth, Houston, TX USA

[43] Univ NSW Sydney, Fac Med, Sch Womens & Childrens Hlth, Sydney, NSW, Australia

[44] Kinghorn Canc Ctr, Garvan Inst Med Res, Sydney, NSW, Australia

[45] Univ NSW Sydney, Lowy Canc Res Ctr, Adult Canc Program, Sydney, NSW, Australia

[46] Yale Sch Publ Hlth, Chron Dis Epidemiol, New Haven, CT USA

[47] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA

[48] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90007 USA

[49] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Oncol, Cambridge, England

[50] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Cambridge, England

来源：

GYNECOLOGIC ONCOLOGY | 2020年 / 158卷 / 03期

基金：

澳大利亚国家健康与医学研究理事会; 英国医学研究理事会; 美国国家卫生研究院;

关键词：

REPLACEMENT THERAPY; WOMEN; CARCINOMA; RISK; PROGNOSIS; ESTROGENS; DISEASE; IMPACT; AGE;

D O I：

10.1016/j.ygyno.2020.06.481

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose. Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival. Methods. Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery. Results. Use of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend <0.01 for duration of MHT use). Residual disease mediated some (17%) of the relationship between MHT and survival. Conclusions. Pre-diagnosis MHT use for 5+ years was a favorable prognostic factor for women with ovarian cancer. This large study is consistent with prior smaller studies, and further work is needed to understand the underlying mechanism. (c) 2020 Elsevier Inc. All rights reserved.

引用

页码：702 / 709

页数：8

共 41 条

[1]

Bebar S, 2000, EUR J GYNAECOL ONCOL, V21, P192

[2] Ovarian cancer and hormone replacement therapy in the Million Women Study [J].

Beral, Valerie ;

Bull, Diana ;

Green, Jane ;

Reeves, Gillian .

LANCET, 2007, 369 (9574) :1703-1710

[3] Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study [J].

Besevic, Jelena ;

Gunter, Marc J. ;

Fortner, Renee T. ;

Tsilidis, Konstantinos K. ;

Weiderpass, Elisabete ;

Onland-Moret, N. Charlotte ;

Dossus, Laure ;

Tjonneland, Anne ;

Hansen, Louise ;

Overvad, Kim ;

Mesrine, Sylvie ;

Baglietto, Laura ;

Clavel-Chapelon, Francoise ;

Kaaks, Rudolf ;

Aleksandrova, Krasimira ;

Boeing, Heiner ;

Trichopoulou, Antonia ;

Lagiou, Pagona ;

Bamia, Christina ;

Masala, Giovanna ;

Agnoli, Claudia ;

Tumino, Rosario ;

Ricceri, Fulvio ;

Panico, Salvatore ;

Bueno-de-Mesquita, H. B. ;

Peeters, Petra H. ;

Jareid, Mie ;

Ramon Quiros, J. ;

Duell, Eric J. ;

Sanchez, Maria-Jose ;

Larranaga, Nerea ;

Chirlaque, Maria-Dolores ;

Barricarte, Aurelio ;

Dias, Joana A. ;

Sonestedt, Emily ;

Idahl, Annika ;

Lundin, Eva ;

Wareham, Nicholas J. ;

Khaw, Kay-Tee ;

Travis, Ruth C. ;

Rinaldi, Sabina ;

Romieu, Isabelle ;

Riboli, Elio ;

Merritt, Melissa A. .

BRITISH JOURNAL OF CANCER, 2015, 113 (11) :1622-1631

[4] FIGO Cancer Report 2018 [J].

Bhatla, Neerja ;

Denny, Lynette .

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2018, 143 :2-3

[5] HORMONE REPLACEMENT THERAPY AND SURVIVAL AFTER SURGERY FOR OVARIAN-CANCER [J].

EELES, RA ;

TAN, S ;

WILTSHAW, E ;

FRYATT, I ;

AHERN, RP ;

SHEPHERD, JH ;

HARMER, CL ;

BLAKE, PR ;

CHILVERS, CED .

BRITISH MEDICAL JOURNAL, 1991, 302 (6771) :259-262

[6] Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial [J].

Eeles, Rosalind A. ;

Morden, James P. ;

Gore, Martin ;

Mansi, Janine ;

Glees, John ;

Wenczl, Miklos ;

Williams, Christopher ;

Kitchener, Henry ;

Osborne, Richard ;

Guthrie, David ;

Harper, Peter ;

Bliss, Judith M. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) :4138-+

[7] Menopausal hormone therapy and mortality among women diagnosed with ovarian cancer in the NIH-AARP Diet and Health Study [J].

Felix, Ashley S. ;

Bunch, Kristen ;

Yang, Hannah P. ;

Arem, Hannah ;

Trabert, Britton ;

Gierach, Gretchen L. ;

Park, Yikyung ;

Lowery, WilliamJ. ;

Brinton, Louise A. .

GYNECOLOGIC ONCOLOGY REPORTS, 2015, 13 :13-17

[8] Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies [J].

Gapstur, S. M. ;

Patel, A. V. ;

Banks, E. ;

Dal Maso, L. ;

Talamini, R. ;

Chetrit, A. ;

Hirsh-Yechezkel, G. ;

Lubin, F. ;

Sadetzki, S. ;

Beral, V. ;

Bull, D. ;

Cairns, B. ;

Crossley, B. ;

Gaitskell, K. ;

Goodill, A. ;

Green, J. ;

Hermon, C. ;

Key, T. ;

Moser, K. ;

Reeves, G. ;

Sitas, F. ;

Collins, R. ;

Peto, R. ;

Gonzalez, C. A. ;

Lee, N. ;

Marchbanks, P. ;

Ory, H. W. ;

Peterson, H. B. ;

Wingo, P. A. ;

Martin, N. ;

Silpisornkosol, S. ;

Theetranont, C. ;

Boosiri, B. ;

Chutivongse, S. ;

Jimakorn, P. ;

Virutamasen, P. ;

Wongsrichanalai, C. ;

Goodman, M. T. ;

Lidegaard, O. ;

Kjaer, S. K. ;

Morch, L. S. ;

Tjonneland, A. ;

Byers, T. ;

Rohan, T. ;

Mosgaard, B. ;

Vessey, M. ;

Yeates, D. ;

Freudenheim, J. L. ;

Titus, L. J. ;

Chang-Claude, J. .

LANCET, 2015, 385 (9980) :1835-1842

[9] EFFECT OF HORMONE REPLACEMENT THERAPY ON INFLAMMATORY BIOMARKERS [J].

Georgiadou, Panagiota ;

Sbarouni, Eftihia .

ADVANCES IN CLINICAL CHEMISTRY, VOL 47, 2009, 47 :59-93

[10] Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation [J].

Grodstein, F ;

Manson, JE ;

Stampfer, MJ .

JOURNAL OF WOMENS HEALTH, 2006, 15 (01) :35-44

← 1 2 3 4 5 →